Last updated: October 6, 2026
Givosiran sodium, marketed as Givlaari by Alnylam Pharmaceuticals, is a specialty RNA-interference therapy for acute hepatic porphyria, or AHP. The product has a small diagnosed population, a high annual treatment cost, orphan-drug protection through 2026, and a commercial model built around chronic administration and specialist-center reimbursement.
Givlaari revenue has expanded since its 2019 U.S. launch, but growth is constrained by disease underdiagnosis, treatment discontinuation, payer controls, and a limited addressable population. The product is unlikely to face conventional small-molecule generic competition in the near term. Its more material risks are market-access pressure, competing RNAi therapies, label limitations, and post-orphan-exclusivity challenges.
What is givosiran sodium and what disease does Givlaari treat?
Givosiran sodium is a subcutaneously administered, chemically modified small interfering RNA, or siRNA, that targets hepatic aminolevulinic acid synthase 1, known as ALAS1. By reducing ALAS1 messenger RNA in the liver, givosiran lowers the production of toxic porphyrin precursors associated with acute hepatic porphyria attacks.
| Item |
Detail |
| Brand |
Givlaari |
| Active ingredient |
Givosiran sodium |
| Company |
Alnylam Pharmaceuticals |
| FDA approval |
November 20, 2019 |
| Indication |
Adults and adolescents aged 12 years and older with AHP |
| Administration |
Subcutaneous injection once monthly |
| U.S. dosing |
2.5 mg/kg once monthly |
| Therapeutic category |
RNAi therapy; metabolic and rare-disease medicine |
| Regulatory pathway |
Orphan drug and priority review |
| Principal competitors |
Hemin, acute-care management, clinical-trial therapies, and potential future RNAi products |
The FDA approved Givlaari based primarily on the ENVISION phase 3 trial, which demonstrated a reduction in annualized porphyria attacks requiring hemin, along with reductions in urinary aminolevulinic acid and porphobilinogen levels. The principal safety concerns include injection-site reactions, nausea, chronic kidney effects, and elevations in transaminases. The label recommends liver-function monitoring and periodic evaluation of renal function where clinically appropriate (U.S. Food and Drug Administration [FDA], 2019).
How large is the givosiran market?
The commercial market is structurally small but economically attractive. AHP includes acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and ALA dehydratase-deficiency porphyria. Many patients remain undiagnosed because symptoms overlap with abdominal, neurologic, psychiatric, and gynecologic conditions.
The U.S. epidemiology is difficult to translate directly into treated patients. Biochemical or genetic prevalence estimates exceed the number of patients with recurrent symptomatic attacks. The effective Givlaari market is therefore determined by:
- confirmed diagnosis;
- attack frequency;
- prior hemin use;
- specialist recognition;
- payer authorization;
- ability to maintain monthly treatment.
Patients with recurrent attacks and high hemin utilization are the most commercially attractive segment. Patients with infrequent attacks may remain on episodic hemin or supportive care instead of initiating a high-cost chronic therapy.
What is Givlaari’s annual treatment cost?
Givlaari launched in the United States with an annual wholesale acquisition cost of approximately $442,000 for a 70-kilogram patient, based on weight-based monthly dosing. Actual net revenue per patient is lower because of rebates, discounts, government-program concessions, and specialty-pharmacy economics.
The economic value proposition is based on avoided hospitalizations, emergency visits, hemin administration, lost productivity, and chronic organ damage. Payers may still impose prior authorization because the annual gross cost is high and the clinical benefit is concentrated in patients with recurrent attacks.
European pricing is generally subject to national health technology assessment and negotiated reimbursement. The commercial model is therefore more fragmented outside the United States.
What has Givlaari’s revenue trajectory been?
Givlaari moved from launch-stage revenue to a durable specialty-product franchise. Alnylam’s reported annual net product revenue has generally increased as diagnosis improves, commercial coverage expands, and physicians gain experience with chronic RNAi treatment.
Reported revenue levels have been approximately as follows:
| Fiscal year |
Givlaari net product revenue |
Commercial interpretation |
| 2020 |
About $33 million |
First full year after U.S. launch; pandemic and diagnosis constraints |
| 2021 |
About $75 million to $90 million |
Expansion of treated-patient base and specialist adoption |
| 2022 |
About $137 million |
Broader reimbursement and greater use in recurrent AHP |
| 2023 |
About $160 million |
Continued growth with a more established commercial footprint |
| 2024 |
About $175 million to $180 million |
Mature rare-disease growth profile with a larger installed base |
The company reports Givlaari within product revenue, while total Alnylam revenue also includes Amvuttra, Onpattro, Oxlumo, collaboration revenue, royalties, and other sources. Givlaari is therefore material to Alnylam’s rare-disease portfolio but is no longer the company’s principal revenue driver.
What is driving Givlaari revenue growth?
Revenue growth depends on patient identification more than on broad primary-care prescribing. The main commercial drivers are:
- Increased genetic and biochemical testing for AHP.
- Referral of recurrent-attack patients to porphyria treatment centers.
- Payer acceptance of prophylactic therapy.
- Substitution of chronic givosiran for repeated hemin treatment.
- International reimbursement expansion.
- Longer treatment duration among responders.
Growth is moderated by the small patient pool, treatment discontinuation, safety monitoring, and the fact that some patients experience fewer attacks without requiring continuous therapy.
How profitable is Givlaari?
Alnylam does not generally disclose standalone product gross margin, operating margin, or free cash flow for Givlaari. The product has the economic characteristics of a high-value orphan medicine:
- high revenue per treated patient;
- low manufacturing volume;
- specialty-distribution requirements;
- substantial post-approval medical-affairs spending;
- regulatory and pharmacovigilance obligations;
- comparatively low direct manufacturing cost per dose relative to selling price.
Standalone profitability is therefore likely stronger than the product’s reported revenue alone indicates, but corporate research, commercial, legal, and infrastructure costs prevent direct attribution of operating income.
How does Givlaari compare with competing treatments?
Givlaari competes primarily against disease management rather than another approved chronic prophylactic AHP drug.
| Treatment |
Role in AHP |
Commercial impact on Givlaari |
| Givlaari |
Monthly prophylaxis for recurrent AHP |
Primary branded therapy |
| Hemin |
Acute attack treatment and prophylaxis in selected cases |
Main incumbent alternative |
| Glucose and supportive care |
Management of selected acute episodes |
Used in lower-severity disease |
| Hospital and emergency treatment |
Rescue care for severe attacks |
Economic comparator in value assessments |
| Future RNAi or gene therapies |
Potential disease modification or pathway suppression |
Longer-term competitive threat |
Hemin remains clinically important, particularly for acute attacks. Givlaari’s commercial case is strongest where recurrent attacks create repeated hospital utilization or chronic hemin exposure.
A future competitor could differentiate through less frequent dosing, improved tolerability, broader porphyria coverage, lower price, or a curative or near-curative mechanism. A therapy that reduces the need for monthly injections would pose a greater threat than a product with similar efficacy and dosing.
What FDA exclusivity protects Givlaari?
Givlaari received U.S. orphan-drug exclusivity for the approved AHP indication. The seven-year orphan exclusivity period runs from the November 20, 2019 approval date and is expected to expire in November 2026, subject to the scope of the indication and statutory exceptions.
Orphan exclusivity prevents FDA approval of another drug for the same disease or condition when the competing product is considered clinically superior only in limited circumstances. It is separate from patent protection and does not prevent all possible competing products.
| Protection |
Estimated status |
| FDA orphan exclusivity |
Expected through November 2026 |
| New chemical entity exclusivity |
Generally four years, ending before orphan exclusivity |
| Five-year NCE exclusivity |
Not the principal protection because givosiran is an orphan-designated product with orphan protection |
| Patent protection |
Potentially extends beyond orphan exclusivity |
| Pediatric exclusivity |
No material public basis to treat it as the central commercial protection |
What patents protect givosiran sodium?
Givlaari’s protection is expected to rely on multiple patent categories rather than a single active-ingredient patent. The relevant categories include:
- givosiran sequence and chemical modifications;
- conjugation of siRNA to N-acetylgalactosamine, or GalNAc;
- pharmaceutical compositions;
- methods of reducing ALAS1 expression;
- treatment of acute hepatic porphyria;
- dosing and administration regimens;
- manufacturing and formulation technologies.
Because givosiran is an oligonucleotide drug, the estate can include platform patents and sequence-specific patents. Alnylam’s broader GalNAc-siRNA technology is also relevant, although the enforceability and commercial value of each patent depends on claim scope, expiration, prosecution history, and whether a competing product uses the same delivery architecture.
What is the Orange Book status of Givlaari?
Givlaari is a prescription drug approved under the full FDA approval pathway, and FDA Orange Book records are relevant to listed patent and exclusivity information. Orange Book coverage does not necessarily capture all Alnylam intellectual property. Platform, manufacturing, process, and method-of-use rights may sit outside the most visible product listing.
A generic applicant seeking approval through an abbreviated pathway would need to address listed patents through a Paragraph IV certification if applicable. For an siRNA product, however, the technical and regulatory pathway is more complex than for a conventional orally administered small molecule. A competitor could also pursue a full application or another regulatory route rather than rely on a standard ANDA strategy.
When does Givlaari lose exclusivity?
The first major U.S. loss-of-exclusivity event is the expected November 2026 expiration of orphan exclusivity. That date does not imply immediate generic launch.
Post-2026 entry depends on:
- active patent expiration dates;
- the scope of listed claims;
- patent litigation;
- FDA approval pathway;
- demonstration of pharmaceutical equivalence or comparable clinical performance;
- manufacturing capability;
- payer willingness to reimburse a follow-on siRNA;
- commercial availability of a competing product.
Patent rights could delay competition beyond orphan exclusivity. Conversely, an entrant could challenge patents before expiry through Paragraph IV litigation or other validity and noninfringement strategies.
What generic entry risks exist for Givlaari?
The near-term generic risk is lower than for a conventional tablet or injectable small molecule. Givosiran is a sequence-defined, chemically modified RNA product with specialized delivery, analytical, and manufacturing requirements.
Key barriers include:
- control of oligonucleotide sequence and chemical modification;
- GalNAc conjugation know-how;
- impurity and double-stranded RNA control;
- dose uniformity and product characterization;
- validated potency assays;
- sterile injectable manufacturing;
- clinical comparability;
- limited commercial scale;
- patent coverage around both product and delivery platform.
The risk is not zero. An ANDA or other follow-on application could target selected patents, and a competitor could develop a differentiated siRNA using a different sequence, conjugate, or delivery system. The greater medium-term risk may come from a clinically distinct AHP therapy than from a conventional generic.
Which companies could challenge Givlaari?
No company has publicly established a broad, approved direct substitute for Givlaari in AHP. Competitive pressure is more likely to emerge from:
- RNAi companies with liver-targeted delivery platforms;
- rare-disease developers pursuing porphyria therapies;
- specialty pharmaceutical companies developing hemin alternatives;
- academic or venture-backed programs using gene editing, gene therapy, or pathway modulation.
Alnylam’s established GalNAc platform, clinical safety database, and specialist relationships create meaningful commercial barriers. A competitor would need either superior efficacy, longer dosing intervals, lower toxicity, or a substantially lower net price.
What licensing deals affect Givlaari?
Givlaari was developed within Alnylam’s RNAi platform rather than through a publicly prominent product-specific acquisition or co-development transaction. Alnylam’s broader intellectual-property and collaboration arrangements have strategic relevance because they support the company’s GalNAc delivery technology and RNAi manufacturing infrastructure.
The absence of a major external commercialization partner gives Alnylam control over pricing, market access, and lifecycle management. It also leaves Alnylam responsible for the full cost of global commercialization and post-market support.
What litigation and settlement risks affect Givlaari?
The principal legal risks are patent validity, claim construction, noninfringement, and competition involving Alnylam’s RNAi delivery platform. Public attention around Alnylam’s broader RNAi patent disputes can affect perceived risk across the portfolio, even when litigation does not target Givlaari specifically.
A future Paragraph IV challenge could produce one of three commercial outcomes:
| Scenario |
Likely market effect |
| No challenge before orphan expiry |
Continued branded sales until patent or regulatory entry |
| Challenge settled with delayed entry |
Revenue erosion begins on a negotiated date |
| Alnylam loses key patents |
Earlier follow-on entry and sharper price pressure |
| No viable follow-on product |
Orphan expiry has limited immediate effect |
There is no established public settlement framework that fixes a Givlaari generic-entry date. Any future settlement would require review of the challenged patents, the entrant’s product, and the regulatory status of the application.
What is Givlaari’s geographic market coverage?
The United States is the core commercial market because it combines high pricing, specialist referral infrastructure, and concentrated reimbursement economics. Givlaari has also received regulatory approvals or commercial access in other major markets, including Europe, where country-level reimbursement determines actual penetration.
Geographic performance depends on:
- national rare-disease policies;
- health technology assessment;
- reimbursement thresholds;
- genetic testing access;
- availability of porphyria centers;
- national tendering and price controls.
International expansion can add treated patients, but it usually produces lower net price per patient than the U.S. market.
What is the outlook for Givlaari’s financial trajectory?
Givlaari is likely to remain a durable specialty product rather than a hypergrowth asset. The most probable trajectory is moderate revenue growth through broader diagnosis and international uptake, followed by slower growth as the treated population matures.
The key financial variables are:
- net patient additions;
- persistence on monthly therapy;
- average dose by patient weight;
- gross-to-net concessions;
- U.S. versus international mix;
- reimbursement approvals;
- competition after November 2026;
- patent durability beyond orphan exclusivity.
The product’s revenue base is defensible because the disease is rare, treatment is specialist-led, and manufacturing is complex. Its ceiling is limited because the eligible patient population is small and many carriers are asymptomatic or infrequently symptomatic.
Key Takeaways
- Givlaari is Alnylam’s monthly GalNAc-siRNA therapy for acute hepatic porphyria.
- U.S. orphan-drug exclusivity is expected to run through November 2026.
- Revenue has grown from roughly $33 million in 2020 to approximately $175 million to $180 million in 2024.
- The commercial market is small, high priced, and dependent on diagnosis and specialist treatment.
- Hemin is the principal incumbent treatment, while future RNAi or gene therapies are the main strategic threat.
- Generic substitution is technically harder than for conventional small-molecule drugs.
- Patent protection may extend beyond orphan exclusivity through sequence, formulation, method-of-use, delivery, and manufacturing claims.
- Givlaari’s most likely post-2026 risk is gradual competitive erosion rather than an immediate generic collapse.
FAQs About Givosiran Sodium Market and Exclusivity
How often is Givlaari administered?
Givlaari is administered by subcutaneous injection once monthly at a weight-based dose of 2.5 mg/kg.
Is Givlaari a biologic?
Givlaari is an siRNA drug and is regulated as a drug product. It is not a monoclonal antibody or a conventional protein biologic, although its manufacturing and follow-on development have biologic-like complexity.
Can hemin be used instead of Givlaari?
Hemin remains an important acute and preventive treatment option. The choice depends on attack frequency, clinical severity, prior treatment, safety considerations, and payer coverage.
Does Givlaari treat the genetic cause of porphyria?
No. Givosiran suppresses ALAS1 expression and reduces toxic precursor production. It does not correct the underlying inherited enzyme defect.
What would most improve Givlaari’s long-term commercial value?
Earlier diagnosis, broader testing, durable treatment persistence, expanded reimbursement, and evidence that chronic therapy prevents long-term renal, hepatic, or neurologic complications would support the product’s long-term value.
References
-
Alnylam Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Alnylam Pharmaceuticals, Inc. (2025). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2019). Givlaari (givosiran) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2019). FDA approves first treatment for patients with acute hepatic porphyria. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D. C., Bissell, D. M., Desnick, R. J., Parker, C., Phillips, J. D., Bonkovsky, H. L., Vassiliou, D., Anderson, K. E., & others. (2019). Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. The New England Journal of Medicine, 380(6), 549-558.
-
Balwani, M., Sardh, E., Ventura, P., Peiro, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Stein, P., Yasuda, M., Harper, P., Anderson, K. E., & others. (2020). Phase 3 trial of RNAi therapy for acute intermittent porphyria. The New England Journal of Medicine, 382(24), 2289-2301.
